Clinical Trial Update: Managed Access Programs for LDK378, Ceritinib

View source ↗

Summary

This update notes that the managed access program for ceritinib (LDK378) is no longer available; sponsor is Novartis Pharmaceuticals, and eligible conditions in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Tumors
• Non-small Cell Lung Cancer

Drugs mentioned

• Zykadia (ceritinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC) | Status: NO_LONGER_AVAILABLE